Sandrine O. T.
- Country
- France
- Department
- Service Oncologie Médicale
Research Overview
- Phase II Randomized Study of FOLFIRI Plus Zimberelimab and Domvanalimab Versus FOLFIRI in Patients With Second-Line Metastatic Gastro-Enteropancreatic or Unknown Origin Neuroendocrine Carcinoma
- Phase III Trial of BI 764532 Plus Carboplatin and Etoposide Versus Carboplatin and Etoposide in Previously Untreated DLL3-Positive Advanced Extrapulmonary Neuroendocrine Carcinoma
- Adjuvant Phase III Randomized Trial of Capecitabine plus Temozolomide Versus Surveillance in R0‑resected Stage I‑III Pancreatic Neuroendocrine Tumors (ADJUPANET)
Data & Insights
Has run more than one trial at 24 of 116 partner sites.
Specializations
Haematological malignancies
Clinical research is centred on acute myeloid leukemia, myelodysplastic syndromes, chronic myeloid leukemia, chronic lymphocytic leukemia, and aggressive lymphoma subtypes, with additional interest in multiple myeloma, Waldenström macroglobulinemia, and other relapsed or refractory blood cancers.
- Acute leukemia
- Myelodysplastic syndrome
- B-cell lymphoma
- Multiple myeloma
- Stem cell transplantation
The therapeutic focus includes targeted therapy, immunotherapy, cell therapy, and transplant-related strategies in hematologic oncology.
Breast cancer and hormone receptor-driven disease
The investigator is actively involved in studies of HER2-positive breast cancer, HER2-negative breast cancer, triple-negative breast cancer, and ER-positive metastatic and early-stage disease, including biomarker-selected populations with BRCA or PIK3CA alterations.
- Triple-negative breast cancer
- HER2-positive breast cancer
- Hormone receptor-positive breast cancer
- ctDNA-guided treatment
- Early and metastatic breast cancer
Therapeutic interests include antibody-drug conjugates, endocrine therapy, and molecularly selected treatment for breast cancer.
Thoracic, gastrointestinal, and hepatobiliary cancers
Research activity spans non-small cell lung cancer, small cell lung cancer, esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, biliary tract cancer, and hepatocellular carcinoma, including advanced and metastatic presentations.
- Non-small cell lung cancer
- Colorectal cancer
- Gastric and gastroesophageal junction cancer
- Pancreatic ductal adenocarcinoma
- Hepatocellular carcinoma
Key therapeutic domains include checkpoint inhibition, targeted treatment, and combination immunotherapy across solid tumours.
Genitourinary and gynaecologic oncology
Clinical interests include prostate cancer, renal cell carcinoma, urothelial carcinoma, ovarian cancer, endometrial cancer, and cervical cancer, with attention to recurrent, metastatic, and high-risk disease.
- Prostate cancer
- Renal cell carcinoma
- Urothelial carcinoma
- Ovarian cancer
- Endometrial cancer
The therapeutic emphasis is on hormonal strategies, immunotherapy, and precision oncology for advanced genitourinary and gynaecologic malignancies.
Sarcomas, rare tumours, and transplant-related complications
Additional research covers soft tissue sarcoma, bone sarcoma, neuroendocrine neoplasms, germ cell tumours, bladder cancer, and selected rare cancers, together with complications linked to allogeneic hematopoietic cell transplantation and graft-versus-host disease.
- Soft tissue sarcoma
- Rare solid tumours
- Neuroendocrine carcinoma
- Germ cell tumours
- Graft-versus-host disease
Therapeutic interests include novel immuno-oncology agents, targeted approaches, and supportive care strategies in uncommon and high-risk cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.